ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4648
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,278.46
0.13%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Sigilon Therapeutics Inc (SGTX)

  7. Sigilon Therapeutics Inc (SGTX) Noticias

SGTX

Sigilon Therapeutics (SGTX)

Sigilon Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:SGTX
FechaHoraFuenteTítuloSímboloCompañía
21/08/202307:22Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:SGTXSigilon Therapeutics Inc
15/08/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SGTXSigilon Therapeutics Inc
14/08/202306:25PR Newswire (US)Lilly Completes Acquisition of Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202315:28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202315:20Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202315:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGTXSigilon Therapeutics Inc
11/08/202315:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGTXSigilon Therapeutics Inc
10/08/202307:31Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:SGTXSigilon Therapeutics Inc
07/08/202307:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGTXSigilon Therapeutics Inc
13/07/202307:18Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202306:35Dow Jones NewsEli Lilly to Acquire Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
29/06/202306:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SGTXSigilon Therapeutics Inc
29/06/202305:57Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:SGTXSigilon Therapeutics Inc
29/06/202305:45PR Newswire (US)Lilly to Acquire Sigilon TherapeuticsNASDAQ:SGTXSigilon Therapeutics Inc
22/05/202315:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SGTXSigilon Therapeutics Inc
22/05/202306:30GlobeNewswire Inc.Sigilon Announces Reverse Stock Split of Common StockNASDAQ:SGTXSigilon Therapeutics Inc
09/05/202307:11Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SGTXSigilon Therapeutics Inc
09/05/202306:30GlobeNewswire Inc.Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business HighlightsNASDAQ:SGTXSigilon Therapeutics Inc
02/05/202308:00PR Newswire (US)Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior AdvisorNASDAQ:SGTXSigilon Therapeutics Inc
18/04/202306:00GlobeNewswire Inc.Sigilon Therapeutics to Present at the Needham Virtual Healthcare ConferenceNASDAQ:SGTXSigilon Therapeutics Inc
06/04/202306:07Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SGTXSigilon Therapeutics Inc
06/04/202306:03Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SGTXSigilon Therapeutics Inc
23/03/202316:01Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:SGTXSigilon Therapeutics Inc
14/03/202315:26Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SGTXSigilon Therapeutics Inc
14/03/202315:15GlobeNewswire Inc.Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsNASDAQ:SGTXSigilon Therapeutics Inc
01/03/202315:37Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SGTXSigilon Therapeutics Inc
10/11/202206:30GlobeNewswire Inc.Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsNASDAQ:SGTXSigilon Therapeutics Inc
04/08/202215:30GlobeNewswire Inc.Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsNASDAQ:SGTXSigilon Therapeutics Inc
08/07/202215:58Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:SGTXSigilon Therapeutics Inc
12/05/202215:05GlobeNewswire Inc.Sigilon Therapeutics Reports First Quarter 2022 Financial Results And Business HighlightsNASDAQ:SGTXSigilon Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SGTX

Su Consulta Reciente

NYSE
BAC
Bank of America
NYSE
MCD
McDonalds
COIN
ETHUSD
Ethereum
NYSE
KO
Coca Cola
USOTC
RHHBY
Roche (QX)
AMEX
XLE
Energy Select Sector SPDR
FX
EURMXN
Euro vs MXN
NASDAQ
TSLA
Tesla
NYSE
NKE
Nike
CCOM
US30
US 30
CCOM
OILBRENT
Brent Oil
AMEX
XLF
Financial Select Sector
AMEX
XLV
Health Care Select Sector
NYSE
CVX
Chevron
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados